RVU

Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Cellular, Transplant, NPM1, Drug resistance, CD34, Exposition, STAT5, Bone marrow, Phosphorylation, RBC, CD71, Society, Therapy, MDS, Pharmacology, Ruxolitinib, ASH, Mutation, Coactivator (genetics), STAT1, Meeting, Syndrome, PST, Glycophorin A, Webcast, Patient, Safety, Acute myeloid leukemia, RVU, AML, DNA (cytosine-5)-methyltransferase 3A, Pharmaceutical industry

Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.

Key Points: 
  • Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.
  • The published clinical and non-clinical data strongly support RVU120’s Phase II development plans presented in October.
  • KRAKOW, Poland, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is held on December 9-12, 2023, in San Diego, California.
  • “The results from the CLI120-001 (RIVER-51) study of RVU120 in patients with r/r-AML and HR-MDS continue to improve over time.

Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023

Retrieved on: 
Thursday, December 7, 2023
TNBC, Breast cancer, EGFR, Therapy, AKT, Cancer, Poster, MEK, RAS, RVU, Bone marrow, Pharmaceutical industry

KRAKOW, Poland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE: RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced promising translational data on RVU120 in combination with MEK inhibitors at the San Antonio Breast Cancer Symposium (SABCS) 2023 being held on December 5–9, 2023, in San Antonio, Texas.

Key Points: 
  • KRAKOW, Poland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE: RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced promising translational data on RVU120 in combination with MEK inhibitors at the San Antonio Breast Cancer Symposium (SABCS) 2023 being held on December 5–9, 2023, in San Antonio, Texas.
  • “Translational studies showed single agent activity of RVU120 in breast cancer mammosphere models in different subtypes.
  • “These findings provide insight into the synergistic potential of the combination in hormone-negative breast cancers – a subtype particularly challenging to treat.
  • These findings highlight the synergistic potential of combining RVU120 with MEK inhibitors in hormone-negative BC, particularly in triple negative breast cancer (TNBC) with EGFR amplification and an active RAS pathway.

Key Legislation (H.R. 3674) Considered During House Energy and Commerce Committee Markup

Retrieved on: 
Thursday, November 30, 2023
Kidney disease, RVU, Policy, USPA, Risk, Peripheral artery disease, Patient, Nephrology, Congress, Energy, Specialist, CMS, Cancer, Retirement, Urology, Medicare, Way, Physician, Ways and means committee, Legislation, Radiation, Hospital, Pharmaceutical industry, Health insurance, Nursing

WASHINGTON, Nov. 29, 2023 /PRNewswire-PRWeb/ -- The Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674), legislation to strengthen community and office-based providers, was considered during the Energy and Commerce Health Subcommittee markup held on November 15.

Key Points: 
  • 3674) , legislation to strengthen community and office-based providers, was considered during the Energy and Commerce Health Subcommittee markup held on November 15.
  • 3674 is bipartisan legislation that aims to stop ongoing cuts to office-based specialists for the next two years.
  • I hope that my colleagues agree to work on this legislation and to land on a path forward that supports access to community care.
  • Failing to do so will contribute to already shocking rates of physician shortages and reduces access to care for patients.

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Bone marrow, RVU, Acute myeloid leukemia, 65th Aggressor Squadron, Safety, Society, ASH, Therapy, Cellular, Patient, Transplant, AML, Pharmaceutical industry, Ruxolitinib

"At this year's ASH conference, we are pleased to present updated clinical and preclinical data that highlight the potential of RVU120 to address hematologic malignancies," said Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics.

Key Points: 
  • "At this year's ASH conference, we are pleased to present updated clinical and preclinical data that highlight the potential of RVU120 to address hematologic malignancies," said Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics.
  • "RVU120 continues to show single-agent clinical activity in patients with AML and HR-MDS, along with a tolerable safety profile.
  • In addition, evidence that RVU120 has cytotoxic and differentiating effects on leukemic stem cells highlight its potential as frontline therapy in AML."
  • Initiation of Ryvu-sponsored studies in AML is planned in Q4 2023, and in the LR-MDS and myelofibrosis studies in H1 2024.

Curonix Provides Reimbursement Update on Neurostimulator Procedure Codes

Retrieved on: 
Tuesday, July 18, 2023
Freedom, American Medical Association, CMS, CPT, Centers for Medicare & Medicaid Services, Spinal cord, PNS, Medicare, Journal, Patient, Physician, AMA, Spinal cord stimulator, RVU, SCS, Health insurance

The CMS Proposed Rule reviews updated work RVUs for Medicare reimbursement rate revisions in recognition of the physician work value performed within PNS procedures.

Key Points: 
  • The CMS Proposed Rule reviews updated work RVUs for Medicare reimbursement rate revisions in recognition of the physician work value performed within PNS procedures.
  • The CPT Editorial Panel revised several neurostimulation CPT procedure codes to provide clarity in the CPT codes descriptors and guidance reflecting the work required by physicians to perform PNS and SCS procedures with current and more advanced technology.
  • Curonix is pleased the AMA approved updates that reflect the entire scope of the physician’s work performed in the PNS and SCS surgical procedures.
  • The CPT codes descriptors clarification for PNS and SCS procedures provides additional clarity for physicians and their dedicated teams,” said Aure Bruneau, CEO of Curonix.

The 2023 Radiology Practice Development Report: Radiologists Read an Average of 4.7 Subspecialties in Daily Practice; Less than Half of Radiologists Feel "Very Confident"

Retrieved on: 
Tuesday, June 20, 2023
Workforce, CT scan, Learning, Pediatrics, Education, Educational Strategy for Developing Societies, Neuroimaging, CCTA, Chest pain, Private practice, Neurosurgery, Nuclear medicine, Radiology, Doctor of Philosophy, NASA Outstanding Public Leadership Medal, Practice, RVU, MRI, Magnetic resonance imaging, Patient, Neuroradiology, Reading, MSK, Entrepreneurship, Elective surgery, News, Arnold, Heart, Nursing, Medical imaging, Neuro

CINCINNATI, June 20, 2023 /PRNewswire-PRWeb/ -- Medality, the leading practice development platform for radiologists and imaging organizations, today announced the release of its 2023 Radiology Practice Development Report. This comprehensive report highlights the most critical training gaps and opportunities in radiology and is based on insights from over 2,700 radiologists across 108 countries.

Key Points: 
  • CINCINNATI, June 20, 2023 /PRNewswire-PRWeb/ -- Medality, the leading practice development platform for radiologists and imaging organizations, today announced the release of its 2023 Radiology Practice Development Report .
  • The report reveals that radiologists are reading across an average of 4.7 subspecialty areas in their daily practice, with 40% reporting they read across all radiology subspecialties.
  • The 2023 Radiology Practice Development Report also finds that confidence levels among current readers in each subspecialty varied widely.
  • Highly experienced radiologists are being asked to read in new areas and new technologies that were not part of their training.

Rocky Vista University to Expand Innovative Virtual Reality Program to New Montana Campus

Retrieved on: 
Wednesday, June 7, 2023
University, Other Technology, Technology, Software, Education, Learning, CT, Partnership, Osteopathic medicine in the United States, Rocky Vista University College of Osteopathic Medicine, Anatomy, Colorado State University, Parker, 3D, Foot, Physiology, RVU, VR, MRI, Student, Mountain West Conference, Virtual reality, Video game, Nursing, Medical imaging

With the launch of its third campus in Billings, Montana, Rocky Vista University will expand its partnership with Perspectus, Inc., a Colorado-based virtual and mixed reality technology firm, enabling more students to study human anatomy in the physical and virtual space.

Key Points: 
  • With the launch of its third campus in Billings, Montana, Rocky Vista University will expand its partnership with Perspectus, Inc., a Colorado-based virtual and mixed reality technology firm, enabling more students to study human anatomy in the physical and virtual space.
  • This technology is just one example of the investment Rocky Vista University (RVU) has made with its flagship Montana College of Osteopathic Medicine (MCOM).
  • The virtual reality program helps RVU achieve these goals, offering ground-breaking technology that expands student access to critical three-dimensional learning.
  • “We’re excited to offer this incredible program to our students on the Montana campus.

Report: Physicians Bill an Average of $3.8 Million a Year to Commercial Insurers

Retrieved on: 
Monday, April 3, 2023
Linda, AMN, Certified Registered Nurse Anesthetist, X-ray, Collection, Patient satisfaction, Physician, Rheumatology, Movement, Government, Crna, Medicare, Relative value unit, Anesthesia, Patient, Practitioner, NPS, Nursing, Diagnosis, RVU, Oncology, Pediatrics, Health care, Pharmaceutical industry

On average, providers tracked in the report submit close to $4 million a year in billing to commercial health insurance companies.

Key Points: 
  • On average, providers tracked in the report submit close to $4 million a year in billing to commercial health insurance companies.
  • General surgeons submit the highest average annual claims among physicians included in the report at $11,669,016, while pediatricians submit the lowest average at $1,323,104.
  • The average billing amount to commercial payors generated by specialist physicians is $4,650,750, according to the report, compared to $1,770,564 for primary care physicians.
  • CRNAs submit an average of $1,750,281 in claims to commercial payors, according to the report, while NPs bill an average of $777,393, underscoring their economic importance.

ThriveAP and Carle Health Partner to Support Advanced Practice Providers Transition to Practice

Retrieved on: 
Monday, March 20, 2023
Organization, Health, App, APP, Partnership, MD, Patient, RVU, Nursing, Pharmaceutical industry

NASHVILLE, Tenn., March 20, 2023 /PRNewswire-PRWeb/ -- ThriveAP announces a new relationship with Carle Health, a vertically integrated healthcare system based in Illinois, aimed to support postgraduate nurse practitioners and physician assistants accelerate their transition to practice.

Key Points: 
  • ThriveAP , the leading transition to practice education solution for advanced practice providers (APPs), will help Carle Health support their APP workforce by furthering their skills knowledge and refining practical application expertise through live and virtual transition to practice curriculums.
  • Carle Health recognizes the value of APPs in a growing healthcare system and is dedicated to supporting their staff as they transition into clinical practice.
  • "Our partnership with ThriveAP allows Carle Health to lead the industry in providing a positive learning environment to support postgraduate APPs.
  • Creason continued, "It is an impactful achievement for ThriveAP to partner with Carle Health."

Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

Retrieved on: 
Thursday, December 22, 2022
RVU, Acceleration, Investment banking, Partnership, Warsaw Stock Exchange, Investment, Therapy, LLS, Leukemia, Supervisory board, MBank, Leukemia & Lymphoma Society, Public offering, Series, Plan, Public, EUR, BioNTech, COVID-19, European Investment Bank, PLN, Pharmaceutical industry, Security (finance)

As a result of the Public Offering, Ryvu has obtained gross proceeds of PLN 250.3 million from institutional and individual investors as well as BioNTech and The Leukemia & Lymphoma Society (LLS).

Key Points: 
  • As a result of the Public Offering, Ryvu has obtained gross proceeds of PLN 250.3 million from institutional and individual investors as well as BioNTech and The Leukemia & Lymphoma Society (LLS).
  • Considering all funds secured – including collaboration payments, European Investment Bank funding, and grants - the Company will have approximately PLN 500 million at its disposal to implement its development plans for 2022-2024.
  • The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) acquired 80,181 shares in the equity issue for approximately PLN 4.5 million.
  • Ryvu's Chief Executive Officer, Pawel Przewiezlikowski, bought 182,000 shares in the share issue for approximately PLN 10 million.